WO1998033512A1 - Oil-free pharmaceutical compositions containing cyclosporin a - Google Patents
Oil-free pharmaceutical compositions containing cyclosporin a Download PDFInfo
- Publication number
- WO1998033512A1 WO1998033512A1 PCT/EP1998/000453 EP9800453W WO9833512A1 WO 1998033512 A1 WO1998033512 A1 WO 1998033512A1 EP 9800453 W EP9800453 W EP 9800453W WO 9833512 A1 WO9833512 A1 WO 9833512A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hard gelatine
- gelatine capsule
- present
- cyclosporin
- polyethylene glycol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Definitions
- the present invention relates to novel pharmaceutical compositions comprising cyclosporin A, also known as ciclosporine, as active agent (hereinafter referred to as cyclosporin).
- cyclosporin A also known as ciclosporine
- active agent hereinafter referred to as cyclosporin
- compositions of the present invention are compositions containing cyclosporin which meet the requirements for approval in the US or elsewhere, yet can be produced in a form administrable as a hard gelatine capsule.
- Such capsules are well known in the art and may be made and filled in conventional manner.
- an oral pharmaceutical composition comprising cyclosporin A in a mixture with (i) a surfactant of HLB value at least 10, and optionally (ii) a viscosity increasing agent and/or (iii) a hydrophilic phase, the hydrophilic phase being a polyethylene glycol and/or a lower alkanol provided that any lower alkanol present is present in less than 12%, preferably less than 10 or 8% of the total weight of the composition, the composition being adapted for filling into, and serving as a centre-fill for, a hard gelatine capsule, and being substantially free of any additional oil.
- the present compositions are based on the use of very few components, e.g.
- a surfactant including associated side products normally arising from its preparation
- a viscosity increasing agent thickener
- an additional hydrophilic phase added to that present in the surfactant chosen from polyethylene glycol and/or a lower alkanol which said lower alkanol is present in an amount of less than 12%, e.g. 8% by weight of the composition.
- Cyclosporin compositions which have been proposed before suffer from the disadvantage that they are not stable in hard gelatine capsules, e.g. over 2 to 3 years and have bioavailability or variability similar to SANDIMMUNE OR NEORAL.
- the present compositions have excellent stability. The capsules do not become brittle.
- the composition contains few other excipients.
- This has the advantage of reducing bulk.
- preferably less than 5%, preferably less than 2% or 1% of lipophilic moieties (oils) apart from those present in the surfactant, or hydrophilic moieties, e.g. alkanols such as ethanol or propylene glycol are present.
- compositions may contain polyethylene glycol.
- This may be a part of the surfactant for example if this is produced by polyethoxylation or added separately. This may be present from e.g. 1 to 40% of the formulation.
- the polyethylene glycol is liquid at 37°C e.g. having a M.W. 200 to 600 daltons.
- the cyclosporin may be present in the usual dosage form for a cyclosporin formulation e.g. 25 mg; 50 mg; 100 mg per weight dosage form.
- the dosage form is e.g. a hard gelatine capsule as known in the art.
- compositions of the invention permit the preparation of solid, semi-solid and liquid compositions containing a cyclosporin in sufficiently high concentration to permit convenient oral administration, while at the same time achieving improved efficacy, e.g. in terms of bioavailability characteristics.
- compositions in accordance with the present invention enable effective cyclosporin dosaging with concomitant enhancement of resorption/bioavailability levels, as well as reduced variability in resorption/bioavailability levels achieved both for individual patients receiving cyclosporin therapy as well as between individuals.
- cyclosporin dosage forms are obtainable providing reduced variability in achieved cyclosporin blood/blood serum levels between dosages for individual patients as well as between individuals/ individual patient groups.
- the invention thus enables reduction of cyclosporin dosage levels required to achieve effective therapy.
- it permits closer standardisation as well as optimisation of on-going daily dosage requirements for individual subjects receiving cyclosporin therapy as well as for groups of patients undergoing equivalent therapy.
- monitoring requirements may be reduced, thus substantially reducing the cost of therapy.
- the present invention also offers a means permitting reduction in the occurrence of undesirable side-effects, in particular nephrotoxic reaction, in patients undergoing cyclosporin therapy.
- compositions are of a small volume, yet stable, thereby increasing patient compliance.
- the surfactant is preferably approved by the FDA, e.g. a GRAS surfactant, e.g.
- Polyethyloxylated castor oil e.g. reaction products of natural or hydrogenated vegetable oils and ethylene glycol, i.e. polyoxyethylene glycolated natural or hydrogenated vegetable oils, for example polyoxyethylene glycolated natural or hydrogenated castor oils.
- Such products may be obtained in known manner, e.g. by reaction of a natural or hydrogenated castor oil or fractions thereof with ethylene oxide, e.g. in a molar ratio of from about 1:35 to about 1:60, with optional removal of free polyethyleneglycol components from the product, e.g. in accordance with the methods disclosed in German Auslegeschriften 1,182,388 and 1,518,819.
- Especially suitable are the various tensides available under the trade name Cremophor.
- Nikkol e.g. Nikkol HCO-60.
- the said product Nikkol HC0-60 is a reaction product of hydrogenated castor oil and ethylene oxide exhibiting the following characteristics: Acid no.
- Such products contain a "hydrophilic portion" of ca. 70 to 90% of fatty acid esters of glycerol polyethylene glycol, as well as fatty acid esters of polyethylene glycols and a hydrophilic portion of polyethylene glycol and glycerol ethoxylates.
- the surfactant is a polyethoxylated hydrogenated castor oil Cremophor RH.
- Polyoxyethylene-sorbitan-fatty acid esters e.g. produced by co- polymerising ethylene oxide with fatty acid esters of a sorbitol and its anhydrides of e.g. mono- and tri- lauryl, palmityl, stearyl and oleyl esters e.g. of the type known and commercially available under the trade name Tween (c.f. Fiedler, loc. cit. pp. 1300-1304) including the products Tween 20 [polyoxyethy lene(20)sorbitanmonolaurate] , 40 [polyoxyethylene(20)sorbitanmonopalmitate] ,
- compositions of the invention are the above products Tween 40 and Tween 80;
- Polyethoxylated glyceryl fatty acid mono esters e.g. of lauryl, stearic, oleyl, or isostearic acid, e.g. those obtainable under the name Tagat O or L.
- Polyoxyethylene mono esters of a saturated Cioto C 22 e.g. Cjg substituted e.g. hydroxy fatty acid; e.g. 12 hydroxy stearic PEG acid, e.g. of PEG about e.g. 600-900 e.g. 660 daltons MW, e.g. SOLUTOL H515 from BASF, Ludwigshafen, Germany.
- An especially preferred product of this class for use in the compositions of the invention is the product Pluronic F68 (poloxamer 188).
- Propylene glycol mono- and di-fatty acid esters such as propylene glycol dicaprylate, propylene glycol dilaurate, propylene glycol hydroxystearate, propylene glycol isostearate, propylene glycol laurate, propylene glycol ricinoleate, propylene glycol stearate and so forth (c.f. Fiedler, loc. cit., pp. 1013 et seq.).
- propylene glycol caprylic-capric acid diester as known and commercially available under the trade name Miglyol 840 (c.f. Fiedler, loc. cit., p. 809).
- ionic surfactants examples include:
- lecithins in particular lecithins (c.f. Fiedler, loc. cit., pp. 731-733).
- Lecithins suitable for use in the compositions of the invention include, in particular, soya bean lecithins.
- Bile salts e.g. alkali metal salts, for example sodium taurocholate.
- lipophilic surfactants for use as surfactant component are, e.g.:
- Trans-esterification products of natural vegetable oil triglycerides and polyalkylene polyols are known from the art and may be obtained e.g. in accordance with the general procedures described in US Patent No. 3,288,824. They include trans-esterification products of various natural (e.g. non-hydrogenated) vegetable oils for example, maize oil, kernel oil, almond oil, ground nut oil, olive oil and palm oil and mixtures thereof with polyethylene glycols, in particular polyethylene glycols having an average molecular weight of from 200 to 800.
- trans-esterification product of the class defined are known and commercially available under the trade name Labrafil [see Fiedler, loc. cit., 707].
- Mono-, di- and mono/di-glycerides, especially esterification products of caprylic or capric acid with glycerol are e.g. those comprising or consisting mainly or essentially of caprylic/capric acid mono- and di-glycerides such as are commercially available under the trade name Imwitor (c.f. loc. cit., pp. 645).
- a particularly suitable product of this class for use in the compositions of the invention is the product Imwitor 742, which is the esterification product of a mixture of ca. 60 p.p.w. caprylic acid and ca. 40 p.p.w. capric acid with glycerol.
- Sorbitan fatty acid esters e.g. of the type known and commercially available under the trade name Span, for example including sorbitan-monolauryl, -monopalmityl, -monostearyl, -tristearyl, -monooleyl and -trioleyl esters - (c.f. Fiedler, loc. cit., pp. 1139-1140);
- Pentaerythritol fatty acid esters and polyalkylene glycol ethers for example pentaerythrite- -dioleate, -distearate, -monolaurate, -polyglycol ether and
- Monoglycerides e.g. glycerol monooleate, glycerol monopalmitate and glycerol monostearate, for example as known and commercially available under the trade names Myvatex, Myvaplex and Myverol (c.f. Fiedler, loc. cit., pp. 836), and acetylated, e.g. mono-and di-acetylated monoglycerides, for example as known and commercially available under the trade name Myvacet (c.f. Fiedler, loc. cit., pp. 835);
- Sterols and derivatives thereof for example cholesterols and derivatives thereof, in particular phytosterols, e.g. products comprising sitosterol, campesterol or stigmasterol, and ethylene oxide adducts thereof, for example soya sterols and derivatives thereof, such as known under the trade name Generol (c.f. Fiedler loc. cit., p.p. 554 and 555) in particular the products Generol 122, 122 E5, 122 E10, and 122 E25.
- Generol c.f. Fiedler loc. cit., p.p. 554 and 555
- surfactants may be complex mixtures containing side products or unreacted starting products involved in the preparation thereof made by e.g. polyoxyethylation may contain another side product, e.g. polyethylene glycol.
- compositions of the invention may also comprise a thickening agent (also referred to as a viscosity increasing agent).
- a thickening agent also referred to as a viscosity increasing agent.
- suitable thickening agents may be of those known and employed in the art, including e.g. pharmaceutically acceptable polymeric materials and inorganic thickening agents which enable the compositions to be filled easily and resists leakage, e.g. thixotropic agents. These should also have the property of dissolving quickly (e.g. within 5 minutes) in the stomach juices or water or at pH
- TPGS Water soluble tocopheryl polyethylene glycol succinic acid esters
- Water soluble celluloses and cellulose derivatives including; alkyl celluloses, e.g. methyl-, ethyl- and propyl-celluloses; hydroxyalkyl-celluloses, e.g. hydroxypropyl-celluloses and hydroxypropylalkyl-celluloses such as hydroxypropyl-methyl-celluloses; acylated celluloses, e.g. cellulose-acetates, cellulose-acetatephthallates, cellulose-acetatesuccinates and hydroxypropylmethyl-cellulose phthallates; and salts thereof such as sodium-carboxymethyl- -celluloses.
- alkyl celluloses e.g. methyl-, ethyl- and propyl-celluloses
- hydroxyalkyl-celluloses e.g. hydroxypropyl-celluloses and hydroxypropylalkyl-celluloses
- acylated celluloses e.g. cellulose-acetates, cellulose-acetatephthallates
- Water soluble polyvinylpyrrolidones including for example poly-N-vinylpyrrolidones and vinylpyrrolidone co-polymers such as vinylpyrrolidone- vinylacetate co-polymers, especially of low molecular weight.
- Examples of such compounds suitable for use in accordance with the present invention are those known and commercially available, e.g. under the trade name Kollidon (or, in the USA, Povidone) (c.f. Fiedler, loc. cit., pp. 694-696), in particular the products Kollidon 30 and 90;
- inorganic thickening agents such as atapulgite, bentonite and silicates including hydrophilic silicon dioxide products, e.g. alkylated (for example methylated) silica gels, in particular colloidal silicon dioxide products as known and commercially available under the trade name Aerosil [c.f. Handbook of Pharmaceutical Excipients, loc. cit., p.p. 253-256] in particular the products Aerosil 130, 200, 300, 380, 0, OX 50, TT 600, MOX 80, MOX 170, LK 84 and the methylated Aerosil R 972.
- hydrophilic silicon dioxide products e.g. alkylated (for example methylated) silica gels, in particular colloidal silicon dioxide products as known and commercially available under the trade name Aerosil [c.f. Handbook of Pharmaceutical Excipients, loc. cit., p.p. 253-256] in particular the products Aerosil 130, 200, 300, 380, 0, OX 50, TT 600, MOX
- compositions may also include one or more further ingredients e.g. in an amount of from 0.1 to 5%, in particular anti-oxidants [e.g. ascorbyl palmitate, butyl hydroxy anisole (BHA), butyl hydroxy toluene (BHT) and tocopherols, e.g. -tocopherol (vitamin E)], flavouring agents and so forth.
- anti-oxidants e.g. ascorbyl palmitate, butyl hydroxy anisole (BHA), butyl hydroxy toluene (BHT) and tocopherols, e.g. -tocopherol (vitamin E)
- BHA butyl hydroxy anisole
- BHT butyl hydroxy toluene
- tocopherols e.g. -tocopherol (vitamin E)
- the cyclosporin will generally be present in an amount of from 5 to 30%, suitably from about 10 to about 25% by weight based on the total weight of the composition absent the hard gelatine capsule.
- Any polyethylene glycol amount when present will generally be present in an amount of from about 15% to about 30%, by weight based on the total weight of the composition absent the hard gelatine capsule;
- any further excipient apart from the surfactant and as thickening agent is preferably present from an amount from 0.1% to 5%, by weight based on the total weight of the composition absent the hard gelatine capsule.
- compositions above may additionally include a thickening agent, though, as previously indicated, this will generally be less preferred.
- the amount of thickening agent present may vary e.g. depending on the required consistency of the end product, e.g. whether it is to be in a thickened flowable form, for example for filling into a capsule. The amount will of course also depend on the nature of the thickening agent chosen.
- the thickeners components (4) when present will be present in an amount of up to about 25% by weight based on the total weight of the composition, more suitably in an amount of up to about 15 or 20% by weight, e.g. in an amount of from 0.5 or 5 up to 15 or 20% by weight based on the total weight of the composition.
- compositions may also include further additives or ingredients, e.g. as hereinbefore described.
- they may comprise antioxidants, e.g. in an amount of up to about 0.5 or 1% by weight based on the total weight of the composition, and sweetening or flavouring agents, e.g. in an amount of up to about 2.5 or 5% by weight based on the total weight of the composition.
- the volume may be kept low and the composition may be filled into a capsule size, 1, 2 or 3.
- compositions have been found to exhibit especially advantageous properties when administered orally, e.g. in terms of both the consistency and high level of bioavailability achieved as defined in standard tests in humans or e.g. beagle dogs.
- tenside materials e.g. bile salts
- they are fully dispersible in aqueous systems comprising such natural tensides and are thus capable of providing microemulsion systems in situ which are stable and do not exhibit precipitation or other disruption of fine particulate structure.
- compositions accordingly represent an especially preferred embodiment of the invention.
- the bioavailability characteristics may be observed in standard clinical trials or in dogs using standard radioimmunoassays for cyclosporins.
- Preferred capsules have a short Tmax.
- the compositions form, on dilution with water, micellar solutions, in which one may be able to detect droplets of, e.g. from 10 to 150 nm in diameter.
- the compositions above will preferably be compounded in orally administerable hard gelatine capsule shells to be unit dosage forms.
- each unit dosage will suitably contain between about 5 or 10 and about 200mg cyclosporin, more suitably between about 15 or 25 and about 150mg, e.g. 25, 50 or lOOmg cyclosporin.
- unit dosage forms in accordance with the invention suitable for administration lx, 2x or 3x up to 5x daily (e.g. depending on the particular purpose of therapy, the phase of therapy etc..) will appropriately comprise e.g. about 25 mg, about 50 mg or about 100 mg cyclosporin per unit dosage.
- Example 1 As for Example 1 but containing additionally 10 mg of TPGS.
- composition shows a bioavailability profile in humans and dogs similar to that of NEORAL, e.g. in terms of AUC, Tmax and Cmax.
- the hard gelatine capsules are stable for at least 2 years and maintain an excellent condition.
Abstract
Description
Claims
Priority Applications (23)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98904156A EP0988046B1 (en) | 1997-01-30 | 1998-01-28 | Oil-free pharmaceutical compositions containing cyclosporin a |
DE29824679U DE29824679U1 (en) | 1997-01-30 | 1998-01-28 | Pharmaceutical compositions |
SI9830695T SI0988046T1 (en) | 1997-01-30 | 1998-01-28 | Oil-free pharmaceutical compositions containing cyclosporin a |
AU62141/98A AU737053B2 (en) | 1997-01-30 | 1998-01-28 | Oil-free pharmaceutical compositions containing cyclosporin A |
CA002278675A CA2278675A1 (en) | 1997-01-30 | 1998-01-28 | Hard gelatine capsules containing pharmaceutical compositions substantially free of any oil |
AT98904156T ATE275963T1 (en) | 1997-01-30 | 1998-01-28 | OIL-FREE PHARMACEUTICAL COMPOSITION CONTAINING CYCLOSPORIN |
PL372850A PL191919B1 (en) | 1997-01-30 | 1998-01-28 | Gelatin capsule with solid film including oil-free pharmaceutically compositions |
GB9917521A GB2335854B (en) | 1997-01-30 | 1998-01-28 | Oil-free pharmaceutical compositions containing cyclosporin A |
US09/284,391 US6475519B1 (en) | 1997-01-30 | 1998-01-28 | Oil-free pharmaceutical compositions containing cyclosporin A |
IL13079798A IL130797A0 (en) | 1997-01-30 | 1998-01-28 | Hard gelatine capsules containing pharmaceutical compositions substantially free of any oil |
SK1020-99A SK285019B6 (en) | 1997-01-30 | 1998-01-28 | Hard gelatine capsule |
BR9807528-4A BR9807528A (en) | 1997-01-30 | 1998-01-28 | Oil-free pharmaceutical compositions containing cyclosporine a |
DE69826272T DE69826272T2 (en) | 1997-01-30 | 1998-01-28 | OIL-FREE PHARMACEUTICAL COMPOSITION CONTAINING CYCLOSPORIN |
HU0500385A HUP0500385A3 (en) | 1998-01-28 | 1998-01-28 | Oil-free pharmaceutical compositions containing cyclosporin a |
JP10532524A JP2000516256A (en) | 1997-01-30 | 1998-01-28 | Oil-free pharmaceutical composition containing cyclosporin A |
DK98904156T DK0988046T3 (en) | 1998-01-28 | 1998-01-28 | Oil-free pharmaceutical compositions containing cyclosporin A |
KR10-2003-7005807A KR20040004416A (en) | 1997-01-30 | 1998-01-28 | Oil-Free Pharmaceutical Compositions Containing Cyclosporin A |
DE19882037T DE19882037T1 (en) | 1997-01-30 | 1998-01-28 | Hard gelatin capsule containing essentially oil-free pharmaceutical compositions |
PL98334850A PL190420B1 (en) | 1997-01-30 | 1998-01-28 | Oil-free pharmaceutical compositions containing cyclosporin a |
HU0001013A HUP0001013A3 (en) | 1997-01-30 | 1998-01-28 | Oil-free pharmaceutical compositions containing cyclosporin a |
NZ336900A NZ336900A (en) | 1997-01-30 | 1998-01-28 | Hard gelatine capsules containing pharmaceutical compositions comprising cyclosporin A and being substantially free of any oil |
IL130797A IL130797A (en) | 1997-01-30 | 1999-07-05 | Hard gelatine capsules containing pharmaceutical compositions substantially free of any oil |
HK00106122A HK1027745A1 (en) | 1997-01-30 | 2000-09-26 | Oil-free pharmaceutical compositions containing cyclosporina. |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9701881.6A GB9701881D0 (en) | 1997-01-30 | 1997-01-30 | Organic compounds |
GB9701881.6 | 1997-01-30 | ||
GB9702594.4 | 1997-02-07 | ||
GBGB9702594.4A GB9702594D0 (en) | 1997-02-07 | 1997-02-07 | Organic compounds |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/284,391 A-371-Of-International US6475519B1 (en) | 1997-01-30 | 1998-01-28 | Oil-free pharmaceutical compositions containing cyclosporin A |
US09/992,584 Continuation US6723339B2 (en) | 1997-01-30 | 2001-11-06 | Oil-free pharmaceutical compositions containing cyclosporin A |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998033512A1 true WO1998033512A1 (en) | 1998-08-06 |
Family
ID=26310891
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1998/000453 WO1998033512A1 (en) | 1997-01-30 | 1998-01-28 | Oil-free pharmaceutical compositions containing cyclosporin a |
Country Status (26)
Country | Link |
---|---|
US (3) | US6475519B1 (en) |
EP (2) | EP0988046B1 (en) |
JP (2) | JP2000516256A (en) |
KR (3) | KR20000069900A (en) |
CN (2) | CN1246058A (en) |
AT (1) | ATE275963T1 (en) |
AU (1) | AU737053B2 (en) |
BR (1) | BR9807528A (en) |
CA (1) | CA2278675A1 (en) |
CY (1) | CY2548B1 (en) |
CZ (1) | CZ295207B6 (en) |
DE (3) | DE29824679U1 (en) |
ES (1) | ES2229473T3 (en) |
GB (2) | GB2335854B (en) |
HK (1) | HK1027745A1 (en) |
HU (1) | HUP0001013A3 (en) |
ID (1) | ID26696A (en) |
IL (2) | IL130797A0 (en) |
NZ (1) | NZ336900A (en) |
PL (1) | PL190420B1 (en) |
PT (1) | PT988046E (en) |
RU (1) | RU2211047C2 (en) |
SG (1) | SG115386A1 (en) |
SK (1) | SK285019B6 (en) |
TR (1) | TR199901686T2 (en) |
WO (1) | WO1998033512A1 (en) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998058629A2 (en) * | 1997-06-20 | 1998-12-30 | Phares Pharmaceutical Research N.V. | Preparation of pharmaceutical compositions |
EP0985412A2 (en) * | 1998-08-18 | 2000-03-15 | Panacea Biotec Limited | Cyclosporin compositions |
WO2000048571A1 (en) * | 1999-02-16 | 2000-08-24 | Novartis Ag | Spontaneously dispersible n-benzoyl staurosporine compositions |
WO2000072867A2 (en) * | 1999-05-28 | 2000-12-07 | Novartis Ag | Substantially oil-free cyclosporin compositions |
WO2002089773A2 (en) * | 2001-05-09 | 2002-11-14 | Novartis Ag | Pharmaceutical compositions comprising cyclosporin |
WO2003068266A1 (en) * | 2002-02-14 | 2003-08-21 | Solvay Pharmaceuticals B.V. | Oral solid solution formulation of a poorly water-soluble active substance |
EP2062571A1 (en) * | 2007-11-21 | 2009-05-27 | Innopharmax Inc. | Self-emulsifying pharmaceutical composition with enhanced bioavailability |
US7919113B2 (en) | 1999-12-30 | 2011-04-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Dispersible concentrate lipospheres for delivery of active agents |
JP2011105754A (en) * | 1997-03-12 | 2011-06-02 | Abbott Lab | Hydrophilic binary systems for administration of cyclosporine |
HRP20040320B1 (en) * | 2001-09-10 | 2012-11-30 | Tibotec Pharmaceuticals Ltd. | Method for the preparation of hexahydro-furo(2,3-b) furan-3-ol |
US8865695B2 (en) | 2009-01-08 | 2014-10-21 | Lipocine Inc. | Steroidal compositions |
US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9498485B2 (en) | 2014-08-28 | 2016-11-22 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
US10561615B2 (en) | 2010-12-10 | 2020-02-18 | Lipocine Inc. | Testosterone undecanoate compositions |
US11433083B2 (en) | 2010-11-30 | 2022-09-06 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US11559530B2 (en) | 2016-11-28 | 2023-01-24 | Lipocine Inc. | Oral testosterone undecanoate therapy |
US11707467B2 (en) | 2014-08-28 | 2023-07-25 | Lipocine Inc. | (17-ß)-3-oxoandrost-4-en-17YL tridecanoate compositions and methods of their preparation and use |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5858401A (en) * | 1996-01-22 | 1999-01-12 | Sidmak Laboratories, Inc. | Pharmaceutical composition for cyclosporines |
CA2278675A1 (en) * | 1997-01-30 | 1998-08-06 | Novartis Ag | Hard gelatine capsules containing pharmaceutical compositions substantially free of any oil |
MY139721A (en) * | 2002-04-19 | 2009-10-30 | Cpex Pharmaceuticals Inc | Pharmaceutical composition |
US7101566B2 (en) * | 2002-06-28 | 2006-09-05 | Ethicon, Inc. | Polymer coated microparticles for sustained release |
GB2391471B (en) * | 2002-08-02 | 2005-05-04 | Satishchandra Punambhai Patel | Pharmaceutical compositions |
AU2004222306A1 (en) * | 2003-03-17 | 2004-09-30 | Albany Molecular Research, Inc. | Novel cyclosporins |
PT1660047E (en) | 2003-08-13 | 2014-02-27 | Biocon Ltd | Micro-particle fatty acid salt solid dosage formulations for therapeutic agents |
US20050059583A1 (en) | 2003-09-15 | 2005-03-17 | Allergan, Inc. | Methods of providing therapeutic effects using cyclosporin components |
WO2005053727A2 (en) * | 2003-11-29 | 2005-06-16 | Sangstat Medical Corporation | Pharmaceutical compositions for bioactive peptide agents |
JP2005255677A (en) * | 2004-02-12 | 2005-09-22 | Nof Corp | Cyclosporine preparation |
US7511013B2 (en) * | 2004-09-29 | 2009-03-31 | Amr Technology, Inc. | Cyclosporin analogues and their pharmaceutical uses |
JP2008514701A (en) * | 2004-09-29 | 2008-05-08 | エーエムアール テクノロジー インコーポレイテッド | Cyclosporine alkyne analogs and their pharmaceutical use |
WO2006041631A2 (en) * | 2004-10-06 | 2006-04-20 | Amr Technology, Inc. | Novel cyclosporin alkynes and their utility as pharmaceutical agents |
US7825087B2 (en) | 2005-04-12 | 2010-11-02 | Elan Pharma International Limited | Nanoparticulate and controlled release compositions comprising cyclosporine |
US20060240051A1 (en) * | 2005-04-26 | 2006-10-26 | Singleton Andy H | Eutectic blends containing a water soluble vitamin derivative |
US7297679B2 (en) | 2005-07-13 | 2007-11-20 | Allergan, Inc. | Cyclosporin compositions |
US7202209B2 (en) | 2005-07-13 | 2007-04-10 | Allergan, Inc. | Cyclosporin compositions |
US20070015693A1 (en) * | 2005-07-13 | 2007-01-18 | Allergan, Inc. | Cyclosporin compositions |
US7288520B2 (en) | 2005-07-13 | 2007-10-30 | Allergan, Inc. | Cyclosporin compositions |
US7276476B2 (en) * | 2005-07-13 | 2007-10-02 | Allergan, Inc. | Cyclosporin compositions |
US20070015691A1 (en) | 2005-07-13 | 2007-01-18 | Allergan, Inc. | Cyclosporin compositions |
US7501393B2 (en) | 2005-07-27 | 2009-03-10 | Allergan, Inc. | Pharmaceutical compositions comprising cyclosporins |
US9839667B2 (en) | 2005-10-14 | 2017-12-12 | Allergan, Inc. | Prevention and treatment of ocular side effects with a cyclosporin |
US7745400B2 (en) * | 2005-10-14 | 2010-06-29 | Gregg Feinerman | Prevention and treatment of ocular side effects with a cyclosporin |
US7696165B2 (en) * | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders |
US7696166B2 (en) * | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders |
WO2008103712A2 (en) * | 2007-02-20 | 2008-08-28 | Bisco, Inc. | Polymerizable dental pulp healing, capping, and lining material and method for use |
EP2164466A1 (en) * | 2007-06-01 | 2010-03-24 | Novo Nordisk A/S | Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier |
PL2910570T3 (en) | 2008-03-18 | 2017-06-30 | Novo Nordisk A/S | Protease stabilized, acylated insulin analogues |
SA109300195B1 (en) | 2008-03-28 | 2013-04-20 | Astrazeneca Ab | A Novel Anti-Cancer Pharmaceutical Composition |
AU2013247047A1 (en) | 2012-04-11 | 2014-10-23 | Novo Nordisk A/S | Insulin formulations |
CN110087674B (en) | 2016-12-16 | 2023-01-03 | 诺和诺德股份有限公司 | Pharmaceutical composition containing insulin |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2230440A (en) * | 1989-02-09 | 1990-10-24 | Sandoz Ltd | Cyclosporin compositions |
EP0589843A1 (en) * | 1992-09-25 | 1994-03-30 | Sandoz Ag | Pharmaceutical compositions containing cyclosporins |
DE4412201A1 (en) * | 1993-04-20 | 1994-11-10 | Rentschler Arzneimittel | New pharmaceutical preparations for oral administration containing cyclosporin |
DE19539860A1 (en) * | 1994-11-03 | 1996-05-09 | Dresden Arzneimittel | Oral cyclosporin formulations |
WO1996036316A1 (en) * | 1995-05-19 | 1996-11-21 | Abbott Laboratories | Self-emulsifying formulations of lipophilic drugs |
WO1997034622A1 (en) * | 1996-03-21 | 1997-09-25 | Sangstat Medical Corporation | Oral cyclosporin formulations |
Family Cites Families (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE738604C (en) | 1935-07-09 | 1943-08-23 | Rudolf Degkwitz Dr | Process for the production of hydrosols with a selectable shape and size of the colloidal particles |
CH240789A (en) | 1942-01-28 | 1946-01-31 | Reichstein Tadeus Dr Professor | Process for the preparation of a new compound of the cyclopentanopolyhydrophenanthrene series. |
GB616190A (en) | 1945-11-06 | 1949-01-18 | Procter & Gamble | Improvements in application of low temperature inter-esterification or alcoholysis to glycerides |
FR1274354A (en) | 1956-03-10 | 1961-10-27 | Surfactants obtained from triglycerides and polyethylene glycol | |
GB1171125A (en) | 1966-06-08 | 1969-11-19 | Glaxo Lab Ltd | Improvements in or relating to Injectable Preparations |
US3954967A (en) | 1971-08-05 | 1976-05-04 | Vanguard Chemical Company, Inc. | Method of producing microcolloidal aqueous emulsions of unsaturated organic insecticidal compounds |
US3813345A (en) | 1971-08-05 | 1974-05-28 | Vanguard Chem Co Inc | Method of producing microcolloidal aqueous emulsions of unsaturated organic compounds |
US4073943A (en) | 1974-09-11 | 1978-02-14 | Apoteksvarucentralen Vitrum Ab | Method of enhancing the administration of pharmalogically active agents |
US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
US4210581A (en) | 1975-11-04 | 1980-07-01 | Sandoz Ltd. | Organic compounds |
CH614931A5 (en) | 1975-11-04 | 1979-12-28 | Sandoz Ag | |
US4146499A (en) | 1976-09-18 | 1979-03-27 | Rosano Henri L | Method for preparing microemulsions |
JPS53107408A (en) | 1977-02-28 | 1978-09-19 | Yamanouchi Pharmaceut Co Ltd | Micellar preparation for rectal infusion |
DE2819094A1 (en) | 1977-05-10 | 1978-11-23 | Sandoz Ag | CYCLOSPORIN DERIVATIVES, THEIR USE AND MANUFACTURING |
SE445174B (en) | 1978-03-07 | 1986-06-09 | Sandoz Ag | PHARMACEUTICAL COMPOSITION CONTAINING A CYCLOSPORIN AND A HEALING SUBSTANCE |
CH641356A5 (en) | 1979-02-27 | 1984-02-29 | Sandoz Ag | Pharmaceutical compositions containing cyclosporin |
US4571926A (en) | 1979-06-22 | 1986-02-25 | Pneumatic Scale Corporation | Apparatus for forming, filling and depositing filled bags into cartons |
JPS6033429B2 (en) | 1980-04-28 | 1985-08-02 | 小野薬品工業株式会社 | Prostaglandin-like compounds |
NZ199915A (en) | 1981-03-11 | 1985-07-12 | Unilever Plc | Treating edible oils to raise melting point thereof |
FR2502951B1 (en) | 1981-04-06 | 1985-12-06 | Sandoz Sa | TOPICAL PHARMACEUTICAL COMPOSITIONS IN THE FORM OF A MICRO-EMULSION |
PH19156A (en) | 1982-02-01 | 1986-01-15 | Sandoz Ltd | Dihydrocyclosporin d in the treatment of multiple sclerosis |
JPS58208215A (en) | 1982-05-31 | 1983-12-03 | Sato Seiyaku Kk | Oil-soluble composition containing fat-soluble vitamin |
DE3225706C2 (en) | 1982-07-09 | 1984-04-26 | A. Nattermann & Cie GmbH, 5000 Köln | Liquid active ingredient formulations in the form of concentrates for microemulsions |
DE3235612A1 (en) | 1982-09-25 | 1984-03-29 | Bayer Ag, 5090 Leverkusen | MICROEMULSIONS |
DE3237814A1 (en) | 1982-10-12 | 1984-04-12 | Warner-Lambert Co., 07950 Morris Plains, N.J. | WATER-FREE EMULSIONS AND USE THEREOF |
DE3315805A1 (en) | 1983-04-30 | 1984-11-08 | Bayer Ag, 5090 Leverkusen | Active substance compositions |
JPS6061535A (en) | 1983-08-24 | 1985-04-09 | エフ・ホフマン・ラ・ロシユ・ウント・コンパニ−・アクチエンゲゼルシヤフト | Pharmaceutical composition |
FR2553661B1 (en) | 1983-10-19 | 1985-12-20 | Rhone Poulenc Sante | NEW PHARMACEUTICALLY ACCEPTABLE MICROEMULSIONS |
DE3406497A1 (en) | 1984-02-23 | 1985-09-05 | Mueller Bernhard Willi Werner | HIGHLY DISPERSAL PHARMACEUTICAL MULTI-COMPONENT SYSTEMS AND METHOD FOR THEIR PRODUCTION |
US4794000A (en) | 1987-01-08 | 1988-12-27 | Synthetic Blood Corporation | Coacervate-based oral delivery system for medically useful compositions |
US4963367A (en) | 1984-04-27 | 1990-10-16 | Medaphore, Inc. | Drug delivery compositions and methods |
US5639724A (en) | 1984-07-24 | 1997-06-17 | Sandoz Ltd. | Cyclosporin galenic forms |
GB8903804D0 (en) | 1989-02-20 | 1989-04-05 | Sandoz Ltd | Improvements in or relating to organic compounds |
DE3580717D1 (en) | 1984-08-02 | 1991-01-10 | Sandoz Ag | PHARMACEUTICAL APPLICATION OF (NVA) 2-CYCLOSPORINE. |
CH662944A5 (en) | 1984-10-18 | 1987-11-13 | Pier Luigi Prof Dr Luisi | PROCEDURE FOR THE PREPARATION OF BIOCOMPATIBLE REVERSE MICROCOMPATIBLES AND THEIR USE. |
DE3444893A1 (en) | 1984-12-08 | 1986-06-12 | Henkel KGaA, 4000 Düsseldorf | METHOD FOR PRODUCING FATTY ACID METHYL ESTERS |
JPS61280435A (en) | 1985-04-04 | 1986-12-11 | Kanji Takada | Lymph orienting preparation of cyclosporin |
JPS61249918A (en) | 1985-04-26 | 1986-11-07 | Yutaka Mizushima | Eye drops |
JPS6224776A (en) | 1985-07-25 | 1987-02-02 | Matsushita Electric Works Ltd | Compression system for picture data |
IL78929A0 (en) | 1985-07-29 | 1986-09-30 | Abbott Lab | Microemulsion compositions for parenteral administration |
US5023271A (en) | 1985-08-13 | 1991-06-11 | California Biotechnology Inc. | Pharmaceutical microemulsions |
US4797272A (en) | 1985-11-15 | 1989-01-10 | Eli Lilly And Company | Water-in-oil microemulsions for cosmetic uses |
SE8601624D0 (en) | 1986-04-11 | 1986-04-11 | Haessle Ab | NEW PHARMACEUTICAL PREPARATIONS |
SE457693B (en) | 1986-07-01 | 1989-01-23 | Drilletten Ab | COMPOSITION WITH REGULATED RELEASE WAS A BIOLOGICAL MATERIAL LOST OR DISPERSED IN AN L2 PHASE |
CA1318589C (en) | 1986-08-14 | 1993-06-01 | Bernard Ecanow | Drug delivery system |
DE3629386A1 (en) | 1986-08-29 | 1988-03-03 | Scherer Gmbh R P | GELATINE CAPSULES AND METHOD FOR THEIR PRODUCTION |
DE3707711A1 (en) | 1987-03-11 | 1988-09-22 | Hoechst Ag | OIL-IN-WATER EMULSIONS, METHOD FOR THEIR PRODUCTION AND THEIR USE |
CA1301642C (en) | 1987-03-30 | 1992-05-26 | Howard Bernard Dawson | Chemical formulations |
US4798823A (en) | 1987-06-03 | 1989-01-17 | Merck & Co., Inc. | New cyclosporin analogs with modified "C-9 amino acids" |
JP2577049B2 (en) | 1987-06-04 | 1997-01-29 | 三共株式会社 | Cyclosporine preparation |
EP0296122B1 (en) | 1987-06-17 | 1993-09-29 | Sandoz Ag | Cyclosporins and their use as pharmaceuticals |
GB2206119B (en) | 1987-06-22 | 1990-10-31 | Merck & Co Inc | A new cyclosporin derivative with modified "8-amino acid" |
US4835002A (en) | 1987-07-10 | 1989-05-30 | Wolf Peter A | Microemulsions of oil in water and alcohol |
HU205010B (en) | 1987-09-15 | 1992-03-30 | Sandoz Ag | Process for producing pharmaceutical compositions comprising compounds soluble up to 1 per cent and having medical activity |
US5756450A (en) | 1987-09-15 | 1998-05-26 | Novartis Corporation | Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms |
IL88076A (en) | 1987-10-28 | 1993-01-14 | Nippon Shinyaku Co Ltd | Fat emulsions as drug carriers |
US4914188A (en) | 1987-11-16 | 1990-04-03 | Merck & Co., Inc. | Novel 6-position cyclosporin analogs as non-immunosuppressive antagonists of cyclosporin binding to cyclophilin |
HU203564B (en) | 1987-12-21 | 1991-08-28 | Sandoz Ag | Process for producing new orthorombos cyclosporin without solvatation |
EP0327280B1 (en) | 1988-01-29 | 1992-03-18 | Sankyo Company Limited | Cyclosporin compositions |
CH679119A5 (en) | 1988-05-13 | 1991-12-31 | Sandoz Ag | |
HU201567B (en) | 1988-07-21 | 1990-11-28 | Gyogyszerkutato Intezet | Process for production of intravenous medical compositions containing cyclosphorin |
KR0148748B1 (en) | 1988-09-16 | 1998-08-17 | 장 크라메르, 한스 루돌프 하우스 | A multiphase cyclosporin composition |
US5342625A (en) * | 1988-09-16 | 1994-08-30 | Sandoz Ltd. | Pharmaceutical compositions comprising cyclosporins |
US6007840A (en) | 1988-09-16 | 1999-12-28 | Novartis Ag | Pharmaceutical compositions comprising cyclosporins |
DE68914929T2 (en) | 1988-09-29 | 1994-08-11 | Shiseido Co Ltd | Emulsified composition. |
FR2638089A1 (en) | 1988-10-26 | 1990-04-27 | Sandoz Sa | NOVEL OPHTHALMIC COMPOSITIONS BASED ON CYCLOSPORINE |
JPH0738771B2 (en) | 1989-01-17 | 1995-05-01 | 花王株式会社 | Liquid edible oil composition |
AU5157590A (en) | 1989-02-06 | 1990-08-24 | Abbott Laboratories | Pharmaceutical compositions for oral administration |
US4996193A (en) | 1989-03-03 | 1991-02-26 | The Regents Of The University Of California | Combined topical and systemic method of administration of cyclosporine |
DD298351A5 (en) | 1989-11-06 | 1992-02-20 | Jenapharm Gmbh,De | METHOD FOR PRODUCING A CARRIER-RELATED MEDICAMENT |
AU6785490A (en) | 1989-12-18 | 1991-06-20 | Kraft General Foods, Inc. | Low-saturate edible oils and transesterification methods for production thereof |
HU208491B (en) | 1990-11-27 | 1993-11-29 | Gyogyszerkutato Intezet | Process for producing oral pharmaceutical composition containing cyclosporin |
US6262022B1 (en) | 1992-06-25 | 2001-07-17 | Novartis Ag | Pharmaceutical compositions containing cyclosporin as the active agent |
FR2683225B1 (en) | 1991-10-31 | 1993-12-31 | Gattefosse Sa | PROCESS FOR IMPROVING A GLYCEROLYZED OIL. |
US5206219A (en) | 1991-11-25 | 1993-04-27 | Applied Analytical Industries, Inc. | Oral compositions of proteinaceous medicaments |
DK0642332T3 (en) | 1992-05-13 | 1997-06-16 | Sandoz Ltd | Ophthalmic preparations containing cyclosporin |
CZ291237B6 (en) * | 1993-04-20 | 2003-01-15 | Novartis Ag | Pharmaceutical preparation for oral administration and containing cyclosporin A |
ES2308955T5 (en) | 1993-09-28 | 2012-04-03 | R.P. Scherer Gmbh | Manufacture of soft gelatin capsules |
DE4340781C3 (en) | 1993-11-30 | 2000-01-27 | Novartis Ag | Liquid preparations containing cyclosporin and process for their preparation |
EP0697214A1 (en) * | 1994-07-19 | 1996-02-21 | Vestar, Inc. | Liposomal cyclosporin pharmaceutical formulations |
KR0167613B1 (en) | 1994-12-28 | 1999-01-15 | 한스 루돌프 하우스, 니콜 케르커 | Cyclosporin-containing soft capsule compositions |
US5827822A (en) | 1996-03-25 | 1998-10-27 | Sangstat Medical Corporation | Cyclosporin a formulations as nanoparticles |
US5834017A (en) | 1995-08-25 | 1998-11-10 | Sangstat Medical Corporation | Oral cyclopsporin formulations |
US5962019A (en) | 1995-08-25 | 1999-10-05 | Sangstat Medical Corporation | Oral cyclosporin formulations |
CA2278675A1 (en) * | 1997-01-30 | 1998-08-06 | Novartis Ag | Hard gelatine capsules containing pharmaceutical compositions substantially free of any oil |
JP4718653B2 (en) * | 1997-03-12 | 2011-07-06 | アボツト・ラボラトリーズ | Hydrophilic two-component system for administration of cyclosporine |
US6008191A (en) | 1997-09-08 | 1999-12-28 | Panacea Biotec Limited | Pharmaceutical compositions containing cyclosporin |
GB9912476D0 (en) * | 1999-05-28 | 1999-07-28 | Novartis Ag | Organic compounds |
-
1998
- 1998-01-28 CA CA002278675A patent/CA2278675A1/en not_active Abandoned
- 1998-01-28 PT PT98904156T patent/PT988046E/en unknown
- 1998-01-28 SK SK1020-99A patent/SK285019B6/en not_active IP Right Cessation
- 1998-01-28 AU AU62141/98A patent/AU737053B2/en not_active Ceased
- 1998-01-28 HU HU0001013A patent/HUP0001013A3/en unknown
- 1998-01-28 KR KR1019997006094A patent/KR20000069900A/en active Search and Examination
- 1998-01-28 JP JP10532524A patent/JP2000516256A/en not_active Withdrawn
- 1998-01-28 PL PL98334850A patent/PL190420B1/en not_active IP Right Cessation
- 1998-01-28 CZ CZ19992663A patent/CZ295207B6/en not_active IP Right Cessation
- 1998-01-28 KR KR10-2003-7005807A patent/KR20040004416A/en not_active Application Discontinuation
- 1998-01-28 AT AT98904156T patent/ATE275963T1/en not_active IP Right Cessation
- 1998-01-28 US US09/284,391 patent/US6475519B1/en not_active Expired - Fee Related
- 1998-01-28 DE DE29824679U patent/DE29824679U1/en not_active Expired - Lifetime
- 1998-01-28 GB GB9917521A patent/GB2335854B/en not_active Expired - Fee Related
- 1998-01-28 NZ NZ336900A patent/NZ336900A/en unknown
- 1998-01-28 WO PCT/EP1998/000453 patent/WO1998033512A1/en not_active Application Discontinuation
- 1998-01-28 KR KR1020057012172A patent/KR20050084502A/en active Search and Examination
- 1998-01-28 EP EP98904156A patent/EP0988046B1/en not_active Revoked
- 1998-01-28 DE DE69826272T patent/DE69826272T2/en not_active Revoked
- 1998-01-28 TR TR1999/01686T patent/TR199901686T2/en unknown
- 1998-01-28 CN CN98802163A patent/CN1246058A/en active Pending
- 1998-01-28 GB GB0024188A patent/GB2355195B/en not_active Expired - Fee Related
- 1998-01-28 IL IL13079798A patent/IL130797A0/en active IP Right Grant
- 1998-01-28 BR BR9807528-4A patent/BR9807528A/en not_active Application Discontinuation
- 1998-01-28 RU RU99118508/14A patent/RU2211047C2/en not_active IP Right Cessation
- 1998-01-28 SG SG200104053A patent/SG115386A1/en unknown
- 1998-01-28 ES ES98904156T patent/ES2229473T3/en not_active Expired - Lifetime
- 1998-01-28 EP EP03007982A patent/EP1331002A3/en not_active Withdrawn
- 1998-01-28 CN CNA2005100666723A patent/CN1679917A/en active Pending
- 1998-01-28 DE DE19882037T patent/DE19882037T1/en not_active Ceased
- 1998-01-29 ID IDW990766A patent/ID26696A/en unknown
-
1999
- 1999-07-05 IL IL130797A patent/IL130797A/en not_active IP Right Cessation
-
2000
- 2000-09-26 HK HK00106122A patent/HK1027745A1/en not_active IP Right Cessation
-
2001
- 2001-11-06 US US09/992,584 patent/US6723339B2/en not_active Expired - Fee Related
-
2004
- 2004-02-18 US US10/781,069 patent/US20040161458A1/en not_active Abandoned
-
2005
- 2005-05-12 JP JP2005139910A patent/JP2005225897A/en active Pending
-
2006
- 2006-02-13 CY CY0600002A patent/CY2548B1/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2230440A (en) * | 1989-02-09 | 1990-10-24 | Sandoz Ltd | Cyclosporin compositions |
EP0589843A1 (en) * | 1992-09-25 | 1994-03-30 | Sandoz Ag | Pharmaceutical compositions containing cyclosporins |
DE4412201A1 (en) * | 1993-04-20 | 1994-11-10 | Rentschler Arzneimittel | New pharmaceutical preparations for oral administration containing cyclosporin |
DE19539860A1 (en) * | 1994-11-03 | 1996-05-09 | Dresden Arzneimittel | Oral cyclosporin formulations |
WO1996036316A1 (en) * | 1995-05-19 | 1996-11-21 | Abbott Laboratories | Self-emulsifying formulations of lipophilic drugs |
WO1997034622A1 (en) * | 1996-03-21 | 1997-09-25 | Sangstat Medical Corporation | Oral cyclosporin formulations |
Cited By (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011105754A (en) * | 1997-03-12 | 2011-06-02 | Abbott Lab | Hydrophilic binary systems for administration of cyclosporine |
US6599527B1 (en) | 1997-06-20 | 2003-07-29 | Phares Pharmaceutical Research N.V. | Preparation of pharmaceutical compositions |
WO1998058629A3 (en) * | 1997-06-20 | 1999-03-18 | Phares Pharm Res Nv | Preparation of pharmaceutical compositions |
AU731397B2 (en) * | 1997-06-20 | 2001-03-29 | Phares Pharmaceutical Research N.V. | Preparation of pharmaceutical compositions |
WO1998058629A2 (en) * | 1997-06-20 | 1998-12-30 | Phares Pharmaceutical Research N.V. | Preparation of pharmaceutical compositions |
EP0985412A2 (en) * | 1998-08-18 | 2000-03-15 | Panacea Biotec Limited | Cyclosporin compositions |
EP0985412A3 (en) * | 1998-08-18 | 2001-05-02 | Panacea Biotec Limited | Cyclosporin compositions |
WO2000048571A1 (en) * | 1999-02-16 | 2000-08-24 | Novartis Ag | Spontaneously dispersible n-benzoyl staurosporine compositions |
US8575147B2 (en) | 1999-02-16 | 2013-11-05 | Novartis Ag | Spontaneously dispersible N-benzoyl staurosporine compositions |
US8722664B2 (en) | 1999-02-16 | 2014-05-13 | Novartis Ag | Spontaneously dispersible N-benzoyl staurosporine compositions |
GB2367004B (en) * | 1999-05-28 | 2004-04-14 | Novartis Ag | A cyclosporin containing composition in the form of a capsule |
GB2367004A (en) * | 1999-05-28 | 2002-03-27 | Novartis Ag | Pharmaceutical compositions |
AU765935B2 (en) * | 1999-05-28 | 2003-10-02 | Novartis Ag | Substantially oil-free cyclosporin compositions |
US6767555B2 (en) | 1999-05-28 | 2004-07-27 | Novartis Ag | Pharmaceutical compositions |
WO2000072867A3 (en) * | 1999-05-28 | 2001-04-05 | Novartis Ag | Substantially oil-free cyclosporin compositions |
WO2000072867A2 (en) * | 1999-05-28 | 2000-12-07 | Novartis Ag | Substantially oil-free cyclosporin compositions |
US7919113B2 (en) | 1999-12-30 | 2011-04-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Dispersible concentrate lipospheres for delivery of active agents |
WO2002089773A3 (en) * | 2001-05-09 | 2003-02-06 | Novartis Ag | Pharmaceutical compositions comprising cyclosporin |
WO2002089773A2 (en) * | 2001-05-09 | 2002-11-14 | Novartis Ag | Pharmaceutical compositions comprising cyclosporin |
HRP20040320B1 (en) * | 2001-09-10 | 2012-11-30 | Tibotec Pharmaceuticals Ltd. | Method for the preparation of hexahydro-furo(2,3-b) furan-3-ol |
WO2003068266A1 (en) * | 2002-02-14 | 2003-08-21 | Solvay Pharmaceuticals B.V. | Oral solid solution formulation of a poorly water-soluble active substance |
KR101014545B1 (en) * | 2002-02-14 | 2011-02-16 | 애보트 헬스케어 프로덕츠 비.브이. | Oral solid solution formulation of a poorly water-soluble active substance |
AU2003208713B2 (en) * | 2002-02-14 | 2007-10-18 | Solvay Pharmaceuticals B.V. | Oral solid solution formulation of a poorly water-soluble active substance |
AU2003208713B9 (en) * | 2002-02-14 | 2003-09-04 | Solvay Pharmaceuticals B.V. | Oral solid solution formulation of a poorly water-soluble active substance |
EP2062571A1 (en) * | 2007-11-21 | 2009-05-27 | Innopharmax Inc. | Self-emulsifying pharmaceutical composition with enhanced bioavailability |
US8865695B2 (en) | 2009-01-08 | 2014-10-21 | Lipocine Inc. | Steroidal compositions |
US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
US11052096B2 (en) | 2009-01-08 | 2021-07-06 | Lipocine Inc. | Steroidal compositions |
US10226473B2 (en) | 2010-11-30 | 2019-03-12 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US10881671B2 (en) | 2010-11-30 | 2021-01-05 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US11433083B2 (en) | 2010-11-30 | 2022-09-06 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9757390B2 (en) | 2010-11-30 | 2017-09-12 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US11364249B2 (en) | 2010-11-30 | 2022-06-21 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9943527B2 (en) | 2010-11-30 | 2018-04-17 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9949985B2 (en) | 2010-11-30 | 2018-04-24 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US11364250B2 (en) | 2010-11-30 | 2022-06-21 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US10716794B2 (en) | 2010-11-30 | 2020-07-21 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US10799513B2 (en) | 2010-11-30 | 2020-10-13 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9480690B2 (en) | 2010-11-30 | 2016-11-01 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US10973833B2 (en) | 2010-11-30 | 2021-04-13 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9205057B2 (en) | 2010-11-30 | 2015-12-08 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US11311555B2 (en) | 2010-11-30 | 2022-04-26 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US10561615B2 (en) | 2010-12-10 | 2020-02-18 | Lipocine Inc. | Testosterone undecanoate compositions |
US11298365B2 (en) | 2014-08-28 | 2022-04-12 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
US9757389B2 (en) | 2014-08-28 | 2017-09-12 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
US9498485B2 (en) | 2014-08-28 | 2016-11-22 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
US11707467B2 (en) | 2014-08-28 | 2023-07-25 | Lipocine Inc. | (17-ß)-3-oxoandrost-4-en-17YL tridecanoate compositions and methods of their preparation and use |
US11872235B1 (en) | 2014-08-28 | 2024-01-16 | Lipocine Inc. | Bioavailable solid state (17-β)-Hydroxy-4-Androsten-3-one esters |
US11559530B2 (en) | 2016-11-28 | 2023-01-24 | Lipocine Inc. | Oral testosterone undecanoate therapy |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6723339B2 (en) | Oil-free pharmaceutical compositions containing cyclosporin A | |
US8722664B2 (en) | Spontaneously dispersible N-benzoyl staurosporine compositions | |
US7235248B2 (en) | Pharmaceutical compositions comprising cyclosporins | |
US6767555B2 (en) | Pharmaceutical compositions | |
CZ301382B6 (en) | Hydrophilic binary systems for administering cyclosporin | |
AU762247B2 (en) | Oil-free pharmaceutical compositions containing cyclosporin A | |
AU2007201773A1 (en) | Oil-free pharmaceutical compositions containing cyclosporin A | |
MXPA99006916A (en) | Oil-free pharmaceutical compositions containing cyclosporin a |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 130797 Country of ref document: IL Ref document number: 98802163.3 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09284391 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998904156 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 62141/98 Country of ref document: AU Ref document number: 1199900532 Country of ref document: VN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019997006094 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999/01686 Country of ref document: TR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 336900 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1999/006916 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV1999-2663 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 102099 Country of ref document: SK |
|
ENP | Entry into the national phase |
Ref document number: 2278675 Country of ref document: CA Ref document number: 2278675 Country of ref document: CA Kind code of ref document: A Ref document number: 1998 532524 Country of ref document: JP Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: PV1999-2663 Country of ref document: CZ |
|
RET | De translation (de og part 6b) |
Ref document number: 19882037 Country of ref document: DE Date of ref document: 19991216 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 19882037 Country of ref document: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 1998904156 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019997006094 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 62141/98 Country of ref document: AU |
|
WWR | Wipo information: refused in national office |
Ref document number: 1019997006094 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998904156 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2005-54 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 50262005 Country of ref document: SK |
|
WWG | Wipo information: grant in national office |
Ref document number: PV1999-2663 Country of ref document: CZ |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8607 |
|
WWR | Wipo information: refused in national office |
Ref document number: PV2005-54 Country of ref document: CZ |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8607 |